Current p53-based therapeutic strategies focus on ectopic expression of wild-type p53 in p53-null tumours or restoration of the p53 pathway in tumours in which p53 is incapacitated by alterations of other pathway components [9]. The gene discussed is TP53; the disease is neoplasm.